Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes

International Journal of Cardiology

Volumn 169, Issue 1, 2013, Pages 17-28

  Tsai, Chin Feng ^a   Yang, Shun Fa ^a,b   Chu, Hsiao Ju ^a   Ueng, Kwo Chang ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aldosterone; Angiotensin; Atrial fibrillation; Fibrosis; Signal transduction

Indexed keywords

ALDOSTERONE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; COLLAGEN 1A; COLLAGEN 3A; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; ATRIAL FIBROSIS; CONTROLLED STUDY; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALDOSTERONE; ANGIOTENSIN; ATRIAL FIBRILLATION; FIBROSIS; SIGNAL TRANSDUCTION;

ALDOSTERONE; ANIMALS; CELL LINE; FIBROSIS; HEART ATRIA; MAP KINASE SIGNALING SYSTEM; MICE; MYOCYTES, CARDIAC; RECEPTOR CROSS-TALK; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID;

EID: 84886748314     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.06.046     Document Type: Article

References (44)

1. M.A. Allessie, J. Ausma, and U. Schotten Electrical, contractile and structural remodeling during atrial fibrillation Cardiovasc Res 54 2002 230 246
2. B. Burstein, and S. Nattel Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation J Am Coll Cardiol 51 2008 802 809
3. D. Li, S. Fareh, T.K. Leung, and S. Nattel Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort Circulation 100 1999 87 95
4. S. Verheule, T. Sato, and T. Everett IV Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1 Circ Res 94 2004 1458 1465
5. A. Frustaci, C. Chimenti, F. Bellocci, E. Morgante, M.A. Russo, and A. Maseri Histological substrate of atrial biopsies in patients with lone atrial fibrillation Circulation 96 1997 1180 1184
6. D. Li, K. Shinagawa, and L. Pang Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
7. J.R. Ehrlich, S.H. Hohnloser, and S. Nattel Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur Heart J 27 2006 512 518
8. A. Goette, T. Staack, and C. Röcken Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation J Am Coll Cardiol 35 2000 1669 1677
9. A. Goette, M. Arndt, and C. Röcken Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans Circulation 101 2000 2678 2681
10. A. Boldt, U. Wetzel, and J. Weigl Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease J Am Coll Cardiol 42 2003 1785 1792
11. K.T. Weber Aldosterone and spironolactone in heart failure N Engl J Med 341 1999 753 755
12. Y. Sun, F.J. Ramires, and K.T. Weber Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion Cardiovasc Res 35 1997 138 147
13. J.C. Reil, M. Hohl, and S. Selejan Aldosterone promotes atrial fibrillation Eur Heart J 33 2012 2098 2108
14. P. Milliez, N. Deangelis, and C. Rucker-Martin Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction Eur Heart J 26 2005 2193 2199
15. S.C. Shroff, K. Ryu, N.L. Martovitz, B.D. Hoit, and B.S. Stambler Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure J Cardiovasc Electrophysiol 17 2006 534 541
16. J. Zhao, J. Li, Y. Li, H. Shan, Y. Gong, and B. Yang Effects of spironolactone on atrial structural remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing Br J Pharmacol 159 2010 1584 1594
17. A. Goette, P. Hoffmanns, W. Enayati, U. Meltendorf, J.C. Geller, and H.U. Klein Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation Am J Cardiol 88 2001 906 909
18. C.T. Tsai, F.T. Chiang, and C.D. Tseng Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation J Am Coll Cardiol 55 2010 758 770
19. O. Amir, R.E. Amir, H. Paz, R. Mor, M. Sagiv, and B.S. Lewis Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure Am J Cardiol 102 2008 326 329
20. F. Zannad, F. Alla, B. Dousset, A. Perez, and B. Pitt Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES) Circulation 102 2000 2700 2706
21. W.C. Claycomb, N.A. Lanson Jr., and B.S. Stallworth HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte Proc Natl Acad Sci 95 1998 2979 2984
22. C.T. Tsai, L.P. Lai, and J.J. Hwang Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation J Hypertens 26 2008 570 582
23. M.F. Rousseau, O. Gurne, and D. Duprez Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy J Am Coll Cardiol 40 2002 1596 1601
24. E.L. Schiffrin, D.J. Franks, and J. Gutkowska Effect of aldosterone on vascular angiotensin II receptors in the rat Can J Physiol Pharmacol 63 1985 1522 1527
25. M.E. Ullian, J.R. Schelling, and S.L. Linas Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses Hypertension 20 1992 67 73
26. V. Robert, C. Heymes, J.S. Silvestre, A. Sabri, B. Swynghedauw, and C. Delcayre Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis Hypertension 33 1999 981 986
27. E. Harada, M. Yoshimura, and H. Yasue Aldosterone induces angiotensin converting-enzyme gene expression in cultured neonatal rat cardiocytes Circulation 104 2001 137 139
28. I. Mazak, A. Fiebeler, and D.N. Muller Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells Circulation 109 2004 2792 2800
29. A. Di Zhang, A.N. Cat, and C. Soukaseum Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling Hypertension 52 2008 1060 1067
30. T. Sugiyama, T. Yoshimoto, and K. Tsuchiya Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells Endocrinology 146 2005 3900 3906
31. 2 + in vascular smooth muscle cells Circ Res 76 1995 973 979
32. W. Chai, I.M. Garrelds, R. de Vries, W.W. Batenburg, J.P. van Kats, and A.H. Danser Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II Hypertension 46 2005 701 706
33. M. Yamada, M. Kushibiki, T. Osanai, H. Tomita, and K. Okumura Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization Cardiovasc Res 79 2008 169 178
34. C.A. Lemarié, S.M.C. Simeone, and A. Nikonova Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors Circ Res 105 2009 852 859
35. D.H. Endemann, R.M. Touyz, M. Iglarz, C. Savoia, and E.L. Schiffrin Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats Hypertension 43 2004 1252 1257
36. M. Young, and J.W. Funder Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rat Endocrinology 145 2004 3153 3157
37. K. Swedberg, F. Zannad, and J.J. McMurray Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study J Am Coll Cardiol 59 2012 1598 1603
38. L.J. Min, M. Mogi, J.M. Li, J. Iwanami, M. Iwai, and M. Horiuchi Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells Circ Res 97 2005 434 442
39. U. Lendeckel, D. Dobrev, and A. Goette Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation Br J Pharmacol 159 2010 1581 1583
40. J.W. Funder Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects Endocrinology 147 2006 5564 5567
41. I.Z. Jaffe, and M.E. Mendelsohn Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells Circ Res 96 2005 643 650
42. A.W. Krug, L. Allenhöfer, and R. Monticone Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways Hypertension 55 2010 1476 1483
43. D. Fraccarollo, S. Berger, and P. Galuppo Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction Circulation 123 2011 400 408
44. R. Khatib, P. Joseph, M. Briel, S. Yusuf, and J. Healey Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials Int J Cardiol 165 2013 17 24